Tag: targets

Almirall + HitGen = novel oral compounds for AD

almirallshare-open innovation

Almirall, S.A. (ALM) and HitGen Ltd, a privately held biotechnology company established since 2012 in Chengdu, China, entered in a multi-target research collaboration to develop novel oral chemical entities (NCE) for patients suffering from moderate to severe atopic dermatitis.

The purpose of this strategic partnership is the identification of advanced hits, to be licensed by Almirall, using HitGen DNA-encoded library. HitGen has a robust platform with extensive libraries (nearly 400 billion compounds), and a strong track record of deal making, which makes it an excellent partner for Almirall.

Under the terms of the agreement, Almirall will provide reagents and material to screen the targets. HitGen will prosecute screening, hit ID, confirmation and early testing against the selected targets leveraging its proprietary unique DEL Screening platform.

Bhushan Hardas, M.D., MBA, Chief Scientific Officer of Almirall, commented that “this agreement keeps us on the track to achieve our goal of becoming a leading medical dermatology company. We look forward to collaborate with HitGen in identifying new molecules with the potential of becoming new treatment options for patients with atopic dermatitis“.

Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen, stated “we are delighted to enter this collaboration with Almirall, a leader in medical dermatology. This collaboration further emphasizes the role of HitGen in the rapidly developing field of DNA-encoded chemistry. We will work closely with Almirall’s scientists to develop novel oral chemical entities to address unmet medical needs in atopic dermatitis“.

About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals by continuous improvement, bringing our innovative solutions where they are needed.

The company, founded almost 75 years ago with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has been key in value creation to society according to its commitment with to major shareholders and through its decision to help others, to understand their challenges and to use Science to provide solutions for real life. Total revenues in 2018 were 811 million euros. More than 1,800 employees are devoted to Science.

For more information, please visit almirall.com

About HitGen

HitGen is a rapidly growing biotech company with headquarters and main research facilities based in Chengdu, China and with a subsidiary in the USA. HitGen has established a platform for small molecule drug centred around the design, assembly and interrogation of DNA encoded chemical libraries (DELs). HitGen’s DELs contain nearly 400 billion novel, diverse, drug-like small molecule and macrocyclic compounds. These compounds are members of DELs synthe-sised from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielding proven results for the discovery of small molecule leads against precedented and un-precedented classes of biological targets. HitGen is collaborating with pharmaceutical, biotech, and chemical companies, foundations and research institutes in North America, Europe, Asia and Africa to discover and develop approaches for novel medicines and agrochemical solutions.

For more information, please visit www.hitgen.com or contact: Dr. Jin Li, Chairman & CEO, HitGen Ltd. Tel: +86 28 85197385 (8001)

 

Digital + omics = unprecedented target-disease associations

AlmirallShare digital technologies

Almirall, S.A. and the group of Computational Genomics from the Life Sciences Department of the Barcelona Supercomputing Center (BSC), have entered into a research collaboration focused on the identification of new targets to treat dermatological diseases.

The aim of this collaboration is to identify new unprecedented target–disease associations using a number of large scale public omics data sources in combination with the unique expertise and phenomenal technological capabilities of the Barcelona Supercomputing Center (BSC). These capabilities will be used by the BSC to re-analyze existing omics datasets from two dermatological diseases within Almirall focus in order to deliver new target opportunities.

Omics refers to the collective technologies used to explore the roles, relationships, and actions of the various types of molecules and processes that make up the cells of an organism, and have been named as genomics, transcriptomics, proteomics, metabolomics, etc. depending on the family of cellular molecules and processes in each case.

Dr. Jorge Beleta, Research Director, Almirall, commented: “We believe that the world class expertise and capabilities of Dr. Torrents´ group at the Barcelona Supercomputing Center will provide an excellent opportunity to integrate the power of the latest digital and omics technologies into our drug discovery platform”.

At the same time, Dr. David Torrents, leader of the Computational Group from the Barcelona Supercomputing Center-Centro Nacional de Supercomputación (BSC-CNS), stated: “For us, collaborating with companies such as Almirall is a great opportunity to apply our research to specific cases and to go on improving processes and methods based on massive data analysis to speed up drug discovery”.

About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients & future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals in its continuous improvement, bringing our innovative solutions where they are needed. The company, founded in 1943 and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM).

Almirall has become a key element of value creation to society according to its commitment with its major shareholders and its decision to help others, to understand their challenges and to use Science to provide them with solutions for real life. Total revenue in 2017 was 755.8 million euros and more than 1,830 employees are devoted to Science.

For more information, please visit almirall.com linkedin.com/company/almirall

About Barcelona Supercomputing Center

BSC is the leading supercomputing center in Spain. It specializes in high-performance computing. It has a dual role: providing infrastructure and a supercomputing service for Spanish and European scientists, and generating knowledge and technology to be transferred to society. It is a Severo Ochoa Center of Excellence, a member of the top-level European research infrastructure PRACE (Partnership for Advanced Computing in Europe) and manages the Spanish Supercomputing Network (RES). BSC is a public consortium owned by the Spanish Government Ministry of Science, Innovation and Universities (60%), the Catalan Government Department of Business and Knowledge (30%) and the Polytechnic University of Catalonia (10%).